In swine post-weaning enteric disease control, Jiawei Baitouweng Powder is deployed as a phytotherapeutic premix intermediate rather than as a direct-feed powder, because raw botanical powders with a bulk density of 0.35–0.45 g/mL and a Hausner ratio above 1.4 segregate rapidly in high-speed feed lines. The most common production route begins with a 1:9 or 1:19 w/w carrier dilution in a horizontal ribbon blender operating at 60–70% fill and 12–18 rpm; the target final feed inclusion rate is typically 0.5–2.0 kg/metric ton, equivalent to 0.05–0.2% w/w of finished feed. The batch is accepted only when the coefficient of variation for anemoside B4 after 10-point sampling remains below 5.0%. Compliance for therapeutic claims falls under Regulation (EU) 2019/6 for EU-formulated medicated feeding stuffs, while the raw powder itself is controlled under GMP Part II for active substances and reviewed against the People’s Republic of China Veterinary Pharmacopoeia 2020 edition monograph for Baitouweng Powder; if the intended claim is non-therapeutic, the boundary is determined by national veterinary prescription law instead of Regulation (EC) No 1831/2003. Downstream production involves in-feed blending through a paddle mixer after the initial 1:19 dilution, with dust extraction at the tipping station to limit operator exposure to inhalable particles below 10 µm. Terminal finished products include 100 g and 500 g oral powder sachets, 5 kg premix bags for feed mills, and top-dress powders for creep feed.

How Is a Herbal Powder with Poor Cold-Water Solubility Converted into Drinking-Water Medication for Broilers?

Native Jiawei Baitouweng Powder forms a settling suspension, not a true aqueous solution, because the saponin-containing botanical matrix retains water-insoluble cell-wall fragments and pectin-like polysaccharides. To produce a water-dispersible granule, the powder is wet-massed with 10–15% w/w maltodextrin and 2–5% w/w PVP K30 as binder in a top-spray fluid-bed granulator, followed by sieving to a D90 below 75 µm. The final drinking-water dilution is typically 0.2–1.0 g of granulated powder per liter of drinking water, with 0.10–0.25% w/w xanthan gum as suspending agent to maintain 24 h dispersion stability; when water hardness exceeds 250 mg/L CaCO₃ equivalent, 0.05% w/w sodium citrate is added as a chelator to preserve yield point. Compliance for medicated drinking-water products is aligned with Regulation (EU) 2019/6 where the product is a veterinary medicinal product, and with Ph. Eur. 2.9.31 laser diffraction particle-size analysis and Ph. Eur. 2.9.3 sieve testing for batch release; where a zootechnical feed-additive route is pursued, the material must instead comply with Regulation (EC) No 1831/2003 and a standing feed-additive authorisation. Published stability data for the finished water-dispersible granule at 40°C/75% RH beyond six months are limited, so a formal VICH GL3 stability protocol is required before assigning a retest date. Terminal finished products include 100 g and 1 kg water-dispersible granules, 500 mL oral suspension sachets, and proportioner pump packs scaled for 500–1,000 birds.

Centrifugal Partitioning and Endotoxin Removal During Aqueous Extraction for Injectables

The powder is not injectable as received; it serves as extraction feedstock for sterile liquid preparations only after a multi-step decontamination train. A typical extraction uses a 10:1 w/w water-to-powder ratio at 95–100°C for 1.5–2.0 h, yielding 12–18% w/w of primary decoction on a dry-solids basis; the decoction is concentrated under vacuum at ≤60°C because anemoside B4-containing saponin fractions degrade or precipitate at higher temperatures. The ratio in the final injectable solution is standardised to 10 mg/mL anemoside B4 equivalent, and the concentrated liquid is chilled at 2–8°C for at least 24 h before 0.45 µm prefiltration to reduce particulate load from pectin and cell-wall debris. Ultrafiltration through a 10 kDa polyethersulfone membrane reduces high-molecular-weight polysaccharides; terminal sterilisation is achieved by autoclaving at 121°C for 15 min only after confirming that the filled vials maintain a pH of 5.0–6.0 and that the solution remains clear. Compliance for this dosage form requires Ph. Eur. 2.6.14 bacterial endotoxin testing with a limit of < 0.5 EU/mg of extract, USP <85> bacterial endotoxins, and sterile manufacture under EU GMP Annex 1; the Chinese Veterinary Pharmacopoeia 2020 edition and national pharmacopoeial injection monographs govern additional pyrogen and visible-particulate criteria. Production-scale failure modes observed on 50 L extraction lines include nozzle blockage during sterile filtration when the chilled extract is not settled for the full 24 h, and batch rejection due to visual precipitation when the final pH drifts above 6.5. Terminal finished products are 10 mL and 100 mL injectable solutions for cattle and swine, packaged in type II glass vials with rubber stoppers.

For tablet and capsule manufacture, direct compression is rejected because the native botanical powder has a bulk density of 0.35–0.45 g/mL and a Hausner ratio above 1.4, which produces unacceptable die-fill variation on rotary tablet presses. Wet granulation is therefore the standard route: the powder is blended with croscarmellose sodium at 2.0–4.0% w/w and granulated with 10–20% w/w PVP K30 solution in a high-shear granulator at impeller 150–200 rpm for 8–12 min; the wet mass is passed through a 1.2 mm screen and dried in a fluid-bed dryer at inlet 60°C to a loss-on-drying below 5.0% w/w. The addition ratio of Jiawei Baitouweng Powder in the final tablet is usually 200–300 mg per unit, with total tablet mass 600–800 mg and magnesium stearate limited to 0.5–1.0% w/w because higher lubricant levels extend disintegration beyond Ph. Eur. 2.9.1 limits of 15 min in water. Hardness is targeted at 40–70 N using a tablet hardness tester, and friability is controlled to < 1.0% w/w under Ph. Eur. 2.9.7. Compliance for export capsules requires adherence to Ph. Eur. 2.9.1 disintegration, Ph. Eur. 2.9.36 powder flow, and USP <1174> powder flow, plus national pharmacopoeial requirements for herbal drug preparations. Terminal finished products include 600 mg and 800 mg film-coated tablets, 300 mg hard gelatin capsules, and pellet-filled capsules for companion animal dosing.

Feed-Mill Premix Carrier Selection and Segregation Control

The dominant process risk in premix production is not the active powder but the particle-size mismatch between the active botanical powder and the selected carrier. When Jiawei Baitouweng Powder is diluted to 5–20% w/w in a carrier before final feed addition, the carrier must have a comparable D50 of 150–250 µm and low hygroscopicity. Calcium carbonate and pre-milled wheat bran are used as carriers, with moisture controlled below 8.0% w/w and oil absorption determined by standard linseed oil titration; carriers with oil absorption above 45 g/100 g are avoided because they coat the active particles and slow release in the gastrointestinal tract. The premix is mixed in a paddle mixer at 15–20 rpm for 8–12 min, with the active powder sandwiched between two carrier layers to reduce dusting; the final feed addition rate is typically 1–5 kg of this premix per metric ton, depending on the clinical severity level and the anemoside B4 assay of the incoming lot. When ambient relative humidity exceeds 60%, the carrier and powder must be pre-dried below 8.0% moisture before blending; otherwise flowability collapses in the paddle mixer and assay variability increases due to clumping. Compliance for premix manufacture is anchored to FAMI-QS Version 6.0, ISO 22000:2018, and HACCP principles under Codex Alimentarius; when exported to the EU as a medicated feedingstuff intermediate, Regulation (EU) 2019/6 applies, while a purely zootechnical premix requires feed-additive authorisation under Regulation (EC) No 1831/2003.

Terminal products are 5 kg and 20 kg multiwall paper sacks with inner polyethylene liners, labelled with active substance concentration per kg and batch-specific mixing validation data.

When a Crude Herbal Powder Is Used in Propylene Glycol-Based Drench Vehicles for Cattle

Oral drench formulations for cattle require the powder to remain suspended under high-viscosity, low-water-activity conditions. A working formulation contains 100–200 g of Jiawei Baitouweng Powder per liter of finished drench, dispersed in a 40:60 v/v propylene glycol–water vehicle with 0.2% w/w carboxymethylcellulose sodium as suspending agent; high-shear dispersion at 3,000 rpm for 15 min reduces the D90 to < 100 µm and prevents nozzle clogging in automatic drenching guns. The production process is a cold compounding route, because heating the powder in propylene glycol above 60°C leads to irreversible aggregation of saponin-rich particles and poor redispersibility after storage. Compliance for this dosage form follows national veterinary prescribing rules and GMP requirements for non-sterile liquids; rheological stability is checked with Ph. Eur. 2.2.10 viscosity measurement, and the suspension must redisperse within 30 s after shaking. The major limitation is that propylene glycol has an osmotic laxative effect, so the dose volume must be justified by a VICH GL43 target animal safety study; published stability data for this specific multi-solvent drench configuration beyond 24 months at 25°C/60% RH are limited. Terminal finished products are 500 mL and 1 L HDPE drench bottles with tamper-evident caps and calibrated dose chambers.